Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far.

Canada's Foreign Affairs Minister Anita Anand Talks Trade Tensions, China
06:48

Spanish Prime Minister Pedro Sanchez Talks ECB Succession
08:34

Microsoft President Brad Smith Talks Investing in the Gulf
14:54